New therapeutic strategy for metastatic prostate cancer patients resistant to standard treatment (Kinase inhibitors to overcome docetaxel resistance)

Medical Xpress / Germans Trias i Pujol Research Institute / Frontiers in Pharmacology ^ | Feb. 2, 2024 | Vicenç Ruiz de Porras et al

[ConservativeMind]

A team of researchers have found a new therapeutic strategy for patients with a specific subtype of metastatic prostate cancer resistant to standard chemotherapy treatment with docetaxel.

In this study, they propose a new treatment based on a combination of kinase inhibitors in patients who inevitably stop responding to docetaxel.

The team found that resistance to this drug is associated with the hyperactivation of the cellular pathways PI3K/AKT and MEK/ERK and have explored the possibility of inhibiting these pathways as a new therapeutic strategy in patients who maintain the function of PTEN, a negative regulatory protein of the PI3K/AKT pathway.

The results of the study have been satisfactory and, for this reason, the team wants to conduct a clinical trial to assess the safety and efficacy of this combination in patients with prostate cancer resistant to docetaxel.

Vicenç Ruiz de Porras and Adrià Bernat-Peguera, ICO-IGTP researchers and co-first authors of the study, state that the results of this study "open the door to a new therapeutic strategy for those patients with PTEN wild-type tumors, who have progressed to docetaxel and in whom, unlike PTEN null patients, the efficacy of AKT inhibitors in monotherapy has not been demonstrated."

[ConservativeMind]

These drugs are available today to be tried.

[ConservativeMind]

The “Take Charge Of Your Health” Ping List
This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.

Email me to get on either the “Common/Top Issues” (20 - 25% fewer pings) or “Everything” list.